Skip to main content
EMBO Molecular Medicine logoLink to EMBO Molecular Medicine
. 2017 May 22;9(7):985. doi: 10.15252/emmm.201707895

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

Jörg T Regula, Peter Lundh von Leithner, Richard Foxton, Veluchamy A Barathi, Chui Ming Gemmy Cheung, Sai Bo Bo Tun, Yeo Sia Wey, Daiju Iwata, Miroslav Dostalek, Jörg Moelleken, Kay G Stubenrauch, Everson Nogoceke, Gabriella Widmer, Pamela Strassburger, Michael J Koss, Christian Klein, David T Shima, Guido Hartmann
PMCID: PMC5494529  PMID: 28533211

Abstract

graphic file with name EMMM-9-985-g001.jpg


This editorial expression of concern is to alert our readership that the data presented in Figures 4 and 5 require further analysis and verification. The scientific record will be updated once this process has been completed.

J.T.R., P.L.v.L., R.F., D.I., E.N., G.W., P.S., C.K., D.T.S., and G.H. agree. The other authors could either not be reached or did not provide a response.


Articles from EMBO Molecular Medicine are provided here courtesy of Nature Publishing Group

RESOURCES